Challenges for the development of new treatment against heart failure pending of ejection fraction
Explore new solutions.
Heart failure is a leading cause of morbidity and mortality worldwide — and despite major therapeutic progress, the need for effective and targeted treatments remains urgent.
This white paper from PhysioStim offers a deep dive into the current challenges of drug development in Heart Failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), with a focus on translational preclinical models and regulatory guidance.
Whether you are a researcher, pharmacologist, or project leader, this white paper is designed to guide your strategic decisions and help you optimize your cardiac drug development path.
Access expert knowledge
on cardiac drug development
Key data on Heart Failure
32%
20%
#1
cause of hospitalization
for people over 65 years old
Of heart failure patients die
within 1 year post-discharge
Of myocarditis cases lead
to HFrEF
Founded in 2000, PhysioStim is a French preclinical CRO specialized in cardiac electrophysiology and pharmacology. For over 25 years, we ve supported pharmaceutical and biotech companies in developing safe and effective therapies for cardiovascular and non-cardiovascular diseases.
We provide scientifically rigorous, tailored preclinical studies, with a strong focus on translational relevance through in vitro, ex vivo, in vivo, and human-based models. Whether assessing safety, exploring efficacy in heart failure, or conducting mechanistic studies, quality, reproducibility, and regulatory compliance remain our top priorities, backed by GLP certification and AAALAC accreditation.
At PhysioStim, every project is unique. We offer customized study designs and flexible collaborations, adapting to your timelines and objectives with transparency, scientific precision, and a customerdriven mindset.
Provide first-in-class cardiovascular expertise to succeed in your preclinical studies. PhysioStim supports you from to discovery stages to clinical development.
Cardiac safety
assays
Human translation platfrom
Consulting
Drug efficacy
Let’s bridge the
preclinical gap together!
Copyright 2025
Copyright 2025